Do high levels of antistreptokinase limit the efficacy of streptokinase in patients with myocardial infarction?
<p><strong>BACKGROUND</strong>: Antistreptokinase antibody in serum of people who had been exposed to streptococcal infections may interfere with thrombolytic effects of streptokinase. Streptokinase is the only thrombolytic medication in Iran, and is the first line treatment in myo...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Vesnu Publications
2012-03-01
|
Series: | ARYA Atherosclerosis |
Online Access: | http://arya.mui.ac.ir/index.php/arya/article/view/397 |